Three Shockwaves Hit Rocket Lab: Insider Sales, a Blue Origin Blast, and SpaceX’s Looming IPO Put a $74.7B Valuation Under Pressure
03.06.2026 - 05:53:17 | boerse-global.de
Rocket Lab investors got hit from three directions at once. Four insiders cashed out $18.4 million in shares just before a rival’s rocket exploded and SpaceX prepared what could be the biggest IPO in history. The stock tumbled 14.7 percent on Monday to $122.39, marking a third straight losing session and leaving it more than 17 percent below its 52-week high of $150.23.
Despite the pullback, the shares are still up roughly 64 percent since the start of the year. The retreat follows a blistering rally that saw the stock gain 367 percent over the past twelve months, a run that priced in a lot of future promise for a company that has yet to turn a GAAP profit.
Insider exits add to the jitters
The timing of the insider transactions has amplified investor anxiety. Between late May and the sell-off, four senior figures sold significant blocks.
Chief operating officer Frank Klein offloaded 36,860 shares under a pre-arranged trading plan, netting about $5.4 million. General counsel Arjun Kampani sold nearly 24,000 shares for roughly $3.5 million. Director Alexander Slusky disposed of 60,000 shares indirectly through a family entity for almost $9 million. President Marvin Clevenger sold a further 3,500 shares for just over $513,000.
Should investors sell immediately? Or is it worth buying Rocket Lab USA?
All four sales — totalling around 124,000 shares — were executed through Rule 10b5-1 plans established in September 2025, which formally preclude insider knowledge at the time of trade. Nonetheless, the proximity to the price slide has left retail investors on edge.
Sector turbulence from a rival’s mishap and a giant’s debut
Last Friday, a Blue Origin New Glenn rocket exploded during an engine test at Cape Canaveral. The blast sent tremors equivalent to a magnitude 2.5 earthquake and heavily damaged the launch tower and infrastructure at Launch Complex-36. The incident has prompted a sector-wide reassessment of risk and valuation.
Compounding the nervousness, SpaceX is targeting June 12 for its long-awaited initial public offering, with expectations of a valuation north of $1.8 trillion. That forces investors to contrast the pricing of smaller space players against a behemoth with proven profitability and a dominant launch cadence.
The broader space trade has suffered too. Intuitive Machines and AST SpaceMobile also saw sharp declines, and the Procure Space ETF lost nearly 11 percent.
Fundamentals still pointing up — but at a steep price
Operationally, Rocket Lab continues to deliver. First-quarter revenue hit $200.3 million, up 63.5 percent year over year, with a GAAP gross margin of 38.2 percent. The backlog swelled to $2.2 billion, a 20.2 percent increase from the prior quarter, underpinned by more than 70 firm launch missions on the manifest.
Management expects second-quarter revenue of $225 million to $240 million, with GAAP gross margins between 33 and 35 percent (38 to 40 percent on an adjusted basis). The company still loses money: adjusted EBITDA is projected at a loss of $20 million to $26 million, while the net loss in Q1 narrowed to $45 million from $60.6 million a year earlier.
Government contracts provide an additional cushion. Rocket Lab recently secured a $90 million U.S. Space Force award to build and operate two geostationary satellites with Heimdall payloads. Combined with earlier Space Development Agency orders, those deals now total more than $1.3 billion. The company also closed its acquisition of Motiv Space Systems, now branded Rocket Lab Robotics, which had previously supplied systems for NASA’s Perseverance rover.
Neutron: the margin maker or breaker
The real test lies with the new Neutron launch vehicle. In the first quarter, Rocket Lab signed 31 new contracts for its Electron and HASTE rockets, plus five dedicated Neutron launches. The first Neutron flight is slated for late 2026. Hardware integration for the maiden mission is under way, along with qualification of the Archimedes engine and work on the second stage and reusable fairings.
If Rocket Lab can convert its hefty backlog into revenue and steadily improve margins as Neutron ramps up, the valuation story gains credibility. Until then, the market is pricing in enormous future success.
Rocket Lab USA at a turning point? This analysis reveals what investors need to know now.
Capital firepower — with a catch
On the financing side, Rocket Lab disclosed on May 20 an agreement that allows it to sell up to $3.0 billion in shares over time. That does not mean an immediate dilution event — it provides flexibility to tap equity markets when needed. For a stock trading at elevated multiples, the mere existence of such an option can weigh on sentiment.
As of March 31, the company held $1.205 billion in cash, plus $177.9 million in short-term marketable securities and $5.5 million in restricted cash. Operating cash outflow was $50.3 million in Q1, a level that is manageable but not limitless given the investment required for Neutron and other growth programmes.
Analyst caution vs. market optimism
Wall Street remains broadly constructive but cautious on price. The consensus rating is a “Moderate Buy,” yet the average price target stands at $97.19 — a notable discount to the current level around $124. After a nearly 370 percent annual run, the valuation at $74.7 billion market capitalisation leaves little room for error.
The recent pullback is less a repudiation of Rocket Lab’s operational progress and more a reality check on its stock price. In the months ahead, attention will focus on Neutron milestones, launch cadence, and visible margin improvement. Until those deliver concrete results, the shares are likely to remain susceptible to every shockwave the sector sends their way.
Ad
Rocket Lab USA Stock: New Analysis - 3 June
Fresh Rocket Lab USA information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
